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Summary
The Myeloma X trial (ISCRTN60123120) registered patients with relapsed
multiple myeloma. Participants were randomised between salvage autolo-
gous stem cell transplantation (ASCT) or weekly cyclophosphamide follow-
ing re-induction therapy. Cytogenetic analysis performed at trial
registration defined t(4;14), t(14;16) and del(17p) as high-risk. The effect
of cytogenetics on time to progression (TTP) and overall survival was
investigated. At 76 months median follow-up, ASCT improved TTP com-
pared to cyclophosphamide (19 months (95% confidence interval [95% CI]
16–26) vs. 11 months (9–12), hazard ratio [HR]: 040, 95% CI: 029–056,
P < 0001), on which the presence of any single high-risk lesion had a
detrimental impact [likelihood ratio test (LRT): P = 0011]. ASCT also
improved OS [67 months (95% CI 59-not reached) vs. 55 months (44–67),
HR: 064, 95% CI: 042–099, P = 00435], with evidence of a detrimental
impact with MYC rearrangement (LRT: P = 0021). Twenty-one (247%)
cyclophosphamide patients received an ASCT post-trial, median OS was
not reached (95% CI: 39-not reached) for these participants compared to
31 months (22–39), in those who did not receive a post-trial ASCT. The
analysis further supports the benefit of salvage ASCT, which may still be
beneficial after second relapse in surviving patients. There is evidence that
this benefit reduces in cytogenetic high-risk patients, highlighting the need
for targeted study in this patient group.
Keywords: relapsed multiple myeloma, cytogenetics, duration of response,
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Genomic landscape analysis in multiple myeloma (MM) has
been recognized as a prognosis-defining criterion for several
decades, especially in newly diagnosed patients, utilising
interphase fluorescence in situ hybridization (iFISH). In par-
ticular, mutation and deletions of the tumour-suppressor
gene, TP53 on chromosome 17 (17p deletion) as well as bal-
anced translocations involving IGH on Ch14q32, particularly
t(4,14), are associated with a poor prognosis, while hyper-
diploidy is associated with improved outcomes (Boyd et al,
2012; Sonneveld et al, 2016). Emergence of poor prognosis
aberrations is postulated as one mechanism of resistant
relapse; patients with multiple poor prognosis aberrations are
described as having “ultra-high-risk” or “double-hit” disease,
and have an even higher risk of death and progression than
those defined as “high-risk” (one poor prognosis aberration)
(Shah et al, 2018). However, there are few data available
about the emergence of refractory clones in patients relapsing
after autologous stem cell transplantation (ASCT).
The British Society of Bone Marrow Transplantation/UK
Myeloma Forum (BSBMT/UKMF) Myeloma X Relapse
(Intensive) trial (ISCRTN60123120), a study in first relapse
of MM, aimed to evolve our understanding of the tumour
genomic landscape by requiring chromosomal analysis for all
patients at trial registration (baseline). Some participants also
had chromosomal analysis results from diagnosis, the major-
ity from the Medical Research Council (MRC) Myeloma IX
trial (ISRCTN684564111), of which the cytogenetic proce-
dures have been published previously (Ross et al, 2010).
The primary and secondary outcomes of the trial have
been published previously (Cook et al, 2014, 2016). The
analysis reported here had two aims. First, to update the pre-
viously reported time-to-event endpoints from randomisa-
tion, for which extended follow-up data to a minimum of
5 years was available: Time to Progression (TTP), Progres-
sion-Free Survival (PFS), second Progression-Free Survival
(PFS2) and Overall Survival (OS). Second, to investigate
whether the presence of cytogenetic abnormalities at trial
registration (baseline) were correlated with response, TTP,
PFS, PFS2 and OS. Exploratory aims considered whether
chromosomal analysis changed over time, reflecting sub-clo-
nal selection (between diagnosis and first relapse) and the
effect of patients in the weekly cyclophosphamide arm receiv-
ing a subsequent salvage ASCT post-trial (treatment switch-
ing) on OS.
Methods
Study design and patients
The BSBMT/UKMF Myeloma X Relapse (Intensive) trial was
a multicentre, randomised, open-label, phase 3 trial. Patients
with symptomatic, measurable MM were eligible for the trial
if they required treatment for first progressive disease [as
defined by the International Myeloma Working Group
(IMWG) criteria (Durie et al, 2006)] at least 18 months fol-
lowing an ASCT (or 12 months following a trial amendment
in 2011). Detailed inclusion and exclusion criteria have been
published previously (Cook et al, 2014). The study was
implemented at 51 National Health Service hospitals in the
UK, for which written informed consent was obtained from
all registered participants. The trial was approved by the
Multi-Centre Research Ethics Committee, UK, institutional
review boards of the participating centres and by the compe-
tent regulatory authority (Medicines and Healthcare Products
Regulatory Agency, UK). Additionally, the study was con-
ducted according to the Declaration of Helsinki and the
principles of International Conference on Harmonization
Guidelines for Good Clinical Practice and was registered with
an appropriate body (ISCRTN60123120). The trial proce-
dures have been described previously (Cook et al, 2014), and
are summarised in the trial CONSORT diagram (Fig 1) and
in the Data S1, together with the randomisation details.
Cytogenetic analyses
Plasma cells were isolated from fresh, unfixed bone marrow
aspirate. Approximately 2 9 106 marrow cells were incubated
with CD138 antibody and plasma cells were recovered using
an immunomagnetic cell selection process (Auto-MACs, Mil-
tenyi Biotec Ltd., Bisley, UK). The recovered plasma cells
were fixed in a suspension in Carnoy’s solution (three parts
methanol and one part acetic acid) and stored at 20°C
until iFISH testing.
iFISH was done in a two-step manner using a threshold
of 10%, with probes for 1p32.3 (CDKN2C), 1q21 (CKS1B),
13q14, IGH and MYC (all from Cytocell Ltd., Cambridge,
UK) set up in a first round and, if an IGH rearrangement
was identified, the additional tests for myeloma-associated
translocations FGFR3/IGH (t(4,14)), MAF/IGH (t(14,16))
and CCND1/IGH (t(11,14)) (all probes from Abbott
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Fig 1. CONSORT Diagram for the BSBMT/UKMF Myeloma X relapse intensive trial. ASCT, autologous stem-cell transplant; BSBMT, British
Society of Bone Marrow Transplantation; FISH, fluorescence in situ hybridization; OS overall survival; PBSC, peripheral blood stem cells; SD,
stable disease; TTP, time to progression; UKMF, UK Myeloma Forum.
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Molecular, Maidenhead, UK) were done as a second round.
Hyperdiploidy was inferred by the presence of an extra chro-
mosome copy number.
An aliquot (2 ll) of fixed plasma cell suspension was placed
on a marked area of a standard microscope slide for each test.
The probes were prepared according to the manufacturer’s
guidance. The cells were air-dried prior to probe application
with no other pre-treatment conditioning. Two microlitres of
probe were added directly to the cell preparation and covered
by a 12 mm diameter glass coverslip and sealed with rubber
glue. The slides were placed on a programmable hot-plate for
co-denaturation of probe and DNA/cells with time and tem-
perature according to the manufacturer’s protocol. Following
overnight hybridisation at 37°C the slides underwent a strin-
gency wash before counter-staining with 40,6-diamidino-2-
phenylindole (DAPI) for visualisation.
iFISH tests were assessed using an AxioPlan2 epi-fluores-
cent microscope (Zeiss UK, Cambridge, UK) and images were
captured using MetaSystems image capture software (https://
metasystems-international.com/). All tests were checked by
two scientists and results reported in line with the European
Myeloma Network Guideline (Ross et al, 2012).
Outcomes and definitions
For the extended follow-up analysis TTP, OS, PFS and PFS2
were considered. The primary outcome, TTP, was defined as
the time from randomisation to the first on-trial record of
progressive disease. OS was defined as the time from ran-
domisation to death. PFS was defined as the time from ran-
domisation to the first on-trial record of progressive disease
or death. Finally, PFS2 was defined as the time from
randomisation to the second on-trial record of progressive
disease or death. If a participant had not experienced the
event of interest by the time of the analysis, then they were
censored at the time at which they were last known to be
event-free.
The subgroup analysis also considered response, defined as
response following both re-induction therapy and randomi-
sation, using the IMWG criteria (Durie et al, 2006). The
endpoint was categorised into; complete response [CR, also
including stringent complete response (sCR)], partial
response [PR, also including very good partial response
(VGPR)], stable disease (SD), progressive disease (PD) and
early death. For response following randomisation the end-
point was also categorised into ≥VGPR (sCR, CR or VGPR)
and <VGPR (PR, SD, PD or early death).
The presence of the cytogenetic characteristics t(4;14), t
(11;14), del(17p), 13q deletion [del(13q)], hyperdiploidy,
MYC rearrangement and an individual’s cytogenetic risk
group at baseline [standard (no high-risk lesions), adverse
(any high-risk lesion)] were investigated as subgroups. Note
that t(4;14), t(14;16) and del(17p) were defined as high-risk
lesions. Other cytogenetic characteristics were considered for
descriptive purposes only [t(14;16), MYC (Normal, re-
arranged, copy-number)], and trichotomous risk groups
[Standard (no high-risk lesions), high-risk (one high-risk
lesion), ultra-high-risk (more than one high-risk lesion)].
The cytogenetic characteristics at baseline represent the
results from the sample taken at trial registration, whereas
the cytogenetic characteristics at diagnosis represent results
from the original diagnosis (collected retrospectively in Mye-
loma X or prospectively if the participant was in MRC Mye-
loma IX). In the event that the cytogenetic characteristics of
an individual had changed between original diagnosis and
baseline the individual was categorised using the results at
baseline for the subgroup analysis.
Statistical analysis
Details of the sample size, recruitment and trial closure have
been published previously (Cook et al, 2014, 2016). The cut-
off date for this analysis was 20 January 2017, when the 5-year
follow-up was complete. Response has the cut-off of 9-July
2013. All analysis was in accordance with the Myeloma X
(Relapse) Intensive Protocol (Version 7 September 2011 URL:
https://ars.els-cdn.com/content/image/1-s2.0-S2352302616300
497-mmc1.pdf), and was pre-specified in the Myeloma X long-
term follow-up Statistical Analysis Plan (dated 2015) and con-
ducted using SAS 9.4 (SAS Institute, Cary, NC, USA), unless
described as post-hoc exploratory analysis, which was not pre-
specified and conducted using STATA 13 (StataCorp, College
Station, TX, USA).
The intention-to-treat (ITT) analysis of TTP, PFS, OS,
PFS2 and response following randomisation included all
individuals randomised to the study. The various subgroup
analysis included all randomised individuals with cytogenetic
analysis for the subgroup under consideration, defined using
the baseline sample. The cytogenetic subgroups were not
mutually exclusive, i.e. patients may have multiple abnormal-
ities detected. Response post-induction included all registered
individuals with cytogenetic analysis. Any changes of cytoge-
netic abnormalities between diagnosis and first relapse (base-
line) were considered descriptively.
Cox proportional hazards regression was used to analyse
the time-to-event endpoints, adjusting for the stratification
factors (length of first remission or plateau and response to
re-induction treatment), and whether or not mobilisation
treatment was received. These models were then extended to
include appropriate interaction terms in order to assess
whether the effect of the randomisation allocation on the
time-to-event endpoints was heterogeneous between the
levels of the investigated subgroups. Likelihood ratio tests
(LRT) were used to test for treatment heterogeneity by sub-
group. Fisher’s exact tests were used to assess whether an
association existed between response and the various cytoge-
netic subgroups. Response post-randomization was analysed
by logistic regression with the appropriate interaction term,
adjusting for the stratification factors of the trial and whether
or not peripheral blood stem cells (PBSC) mobilisation
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therapy was received, and an LRT conducted to test for treat-
ment heterogeneity.
In an exploratory post-hoc analysis, OS was considered
using the rank-preserving structural failure time model
(RPSFTM) approach (White et al, 1999; Watkins et al, 2013)
to take into account patients in the weekly cyclophos-
phamide group, who received a subsequent salvage ASCT for
the treatment of second, third or subsequent relapse off-trial.
The RPSFTM method estimates the counterfactual ran-
domised treatment effect by considering what the follow-up
time of the participant would have been if they had not
switched to the alternative treatment, under the assumption
that the overall treatment effect is constant irrespective of
when the treatment switch occurs.
This study is registered with ClinicalTrials.gov (NCT00747
877) and EudraCT (2006-005890-24).
Results
Two hundred and ninety-seven patients were registered to the
trial between 16 April 2008 and 19 November 2012, of which
149 patients (502%) had cytogenetic analysis at baseline. The
ITT population considered 174 randomised participants
(Table I), 88 (505%) of which had cytogenetic analysis at
baseline, 43 (489%) in the salvage ASCT group and 45
(511%) in the weekly cyclophosphamide group. There were
no substantial differences between patients with and without
cytogenetic analysis at baseline (Table SI). Similarly, there were
no substantial differences in the baseline characteristics of the
randomised groups when considering those who had cytoge-
netic analysis measured at; diagnosis, first relapse (baseline)
and both, or at least one time point (Tables SII–SV).
Forty-one registered patients had cytogenetic results at
diagnosis and first relapse (baseline). The majority of patients
[n = 34 (829%)] had the same cytogenetic risk group at
both time points (Fig 2). The largest variation within the
individual cytogenetic components was in hyperdiploidy; 11
(268%) patients showed hyperdiploidy at diagnosis but not
at first relapse while two (49%) patients gained this feature.
Similarly, four (98%) patients had del(13q) at diagnosis but
not at first relapse, with one (24%) patient gaining this
characteristic at first relapse. In summary, five (122%)
patients evolved to high-risk disease at first relapse, having
been defined as standard risk at diagnosis, while two (49%)
patients became standard risk at first relapse despite being
high-risk at diagnosis with four (98%) patients retaining
high-risk cytogenetics at both times. Note that MYC was not
considered here as it was not tested for at diagnosis.
As has previously been demonstrated in first-line therapy,
there was no evidence to suggest an association between any
of the genetic abnormalities studied and depth of response
(sCR or CR VGPR or PR, SD or PD) following re-induction
or randomisation to consolidation. Similarly, no impact on
depth of response (<VGPR or ≥VGPR) was evident post-ran-
domisation (Figure S1).
The median follow-up of this study was 76 months (Inter-
quartile range (IQR): 60–83 months). In total there have been
158 disease progressions of 174 randomised patients i.e.
908% of all randomized participants have had documented
PD on trial. In the salvage ASCT group there have been 77
(865%) progressions compared to 81 (953%) in the weekly
cyclophosphamide group. The updated TTP analysis contin-
ues to show a significant advantage for salvage ASCT com-
pared to weekly cyclophosphamide [19 months (95%
confidence interval (95% CI): 16–26 vs. 11 months (9–12)].
Figure 3A shows the Kaplan-Meier curve for TTP stratified by
randomisation allocation. Cox proportional hazards regres-
sion (adjusted for stratification factors and PBSC mobilisa-
tion) showed a reduced hazard of progression in the salvage
ASCT group compared with weekly cyclophosphamide [haz-
ard ratio (HR): 040, 95% CI: 029–056, P < 0001].
The treatment effects for those with cytogenetic analysis at
baseline and the whole ITT population are consistent (HR:
040, 95% CI: 024–065). Figure 3B shows a forest plot of the
TTP results correlated with the cytogenetic analysis at baseline.
There is significant evidence of heterogeneity of treatment
effect with del(13q) (LRT: P = 0044) and MYC rearrange-
ments (LRT: P = 0002). This heterogeneity of treatment effect
is also observed in patients with standard and adverse cytoge-
netics (LRT: P = 0011). In each case the presence of the mar-
ker has a deleterious impact on the randomised treatment
effect observed, compared with the subset of patients without
the marker. The deleterious impact of the presence of MYC
rearrangements can be seen further in Kaplan-Meier curves for
TTP, stratified by whether MYC was rearranged or normal for
each treatment allocation (Figure S2).
There have been 160 PFS events in 174 randomised
patients (920%). In the salvage ASCT group, 79 PFS events
(888%) have been confirmed compared to 81 (953%) in
the weekly cyclophosphamide group. Median PFS was
19 months (95% CI: 16–25) for the salvage ASCT group and
11 months (9–12) for the weekly cyclophosphamide group.
Figure 3C shows the Kaplan-Meier curve for PFS stratified
by randomisation allocation. Cox proportional hazards
regression (adjusted for stratification factors and PBSC
mobilisation) showed a reduced hazard of death in the sal-
vage ASCT group compared with weekly cyclophosphamide
(HR: 041, 95% CI: 030–058, P < 0001).
The treatment effects for those with cytogenetic analysis at
baseline and the ITT population are consistent (HR: 041,
95% CI: 025–066). Figure 3D shows a forest plot of the PFS
results correlated with the cytogenetic analysis at baseline.
There is significant evidence of heterogeneity of treatment
effect with MYC rearrangement (LRT: P = 0003) as well as
standard versus adverse comparisons (LRT: P = 0014). In
each case the presence of the marker has a deleterious impact
on the randomised treatment effect observed, compared with
the subset of patients without the marker.
There have been 112 PFS2 events in 174 randomised
patients (644%), with 47 second progressions or deaths
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Table I. Baseline characteristics of patients in the intention-to-treat population.
Registered
(n = 297)
Salvage ASCT
(n = 89)
Weekly cyclophosphamide
(n = 85)
Randomised
(n = 174)
Age at baseline, years
Median (IQR) 61 (55, 65) 61 (56, 64) 61 (54, 65) 61 (56, 65)
Patient gender
Male 208 (700%) 65 (730%) 61 (718%) 126 (724%)
Female 89 (300%) 24 (270%) 24 (282%) 48 (276%)
Patient race
White 267 (899%) 81 (910%) 80 (941%) 161 (925%)
Mixed – White and
Black Caribbean
1 (03%) 0 (00%) 0 (00%) 0 (00%)
Asian – Indian 3 (10%) 1 (11%) 2 (24%) 3 (17%)
Asian – Pakistani 1 (03%) 1 (11%) 0 (00%) 1 (06%)
Asian – Bangladeshi 1 (03%) 0 (00%) 0 (00%) 0 (00%)
Other Asian background 2 (07%) 1 (11%) 0 (00%) 1 (06%)
Black – Caribbean 8 (27%) 2 (22%) 1 (12%) 3 (17%)
Black – African 4 (13%) 1 (11%) 0 (00%) 1 (06%)
Other Black background 2 (07%) 0 (00%) 1 (12%) 1 (06%)
Other ethnic group 2 (07%) 0 (00%) 0 (00%) 0 (00%)
Not stated 3 (10%) 2 (22%) 1 (12%) 3 (17%)
Missing 3 (10%) 0 (00%) 0 (00%) 0 (00%)
Paraprotein type
IgG 190 (640%) 60 (674%) 57 (671%) 117 (672%)
IgA 55 (185%) 13 (146%) 18 (212%) 31 (178%)
IgM 1 (03%) 1 (11%) 0 (00%) 1 (06%)
IgD 2 (07%) 0 (00%) 1 (12%) 1 (06%)
Light chain only 28 (94%) 7 (79%) 7 (82%) 14 (80%)
Non-secretor 9 (30%) 3 (34%) 2 (24%) 5 (29%)
Missing 12 (40%) 5 (56%) 0 (00%) 5 (29%)
Light chain type
Lambda 82 (276%) 24 (270%) 21 (247%) 45 (259%)
Kappa 185 (623%) 52 (584%) 59 (694%) 111 (638%)
Missing 30 (101%) 13 (146%) 5 (59%) 18 (103%)
ISS at baseline
I 188 (633%) 57 (640%) 51 (600%) 108 (621%)
II 61 (205%) 18 (202%) 21 (247%) 39 (224%)
III 27 (91%) 8 (90%) 4 (47%) 12 (69%)
Missing 21 (71%) 6 (67%) 9 (106%) 15 (86%)
Previous treatment response length
<18 months N/A 3 (34%) 2 (24%) 5 (29%)
18–24 months N/A 22 (247%) 19 (224%) 41 (236%)
>24 months N/A 64 (719%) 64 (753%) 128 (736%)
Response to re-induction treatment
SD N/A 7 (79%) 5 (59%) 12 (69%)
More than PR (PR, VGPR, CR or sCR) N/A 82 (921%) 80 (941%) 162 (931%)
PBSC mobilisation and harvest given
Yes N/A 44 (494%) 26 (306%) 70 (402%)
No N/A 43 (483%) 56 (659%) 99 (569%)
Missing data N/A 2 (22%) 3 (35%) 5 (29%)
iFISH cytogenetic results at diagnosis
Yes 63 (212%) 20 (225%) 26 (306%) 46 (264%)
No 234 (788%) 69 (775%) 59 (694%) 128 (736%)
iFISH cytogenetic results at baseline
Yes 149 (502%) 43 (483%) 45 (529%) 88 (506%)
No 148 (498%) 46 (517%) 40 (471%) 86 (494%)
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(528%) confirmed in the salvage ASCT group compared to
65 (765%) in the weekly cyclophosphamide group. Median
PFS2 was 62 months (95% CI: 47–72) for the salvage ASCT
group and 35 months (31–46) in the weekly cyclophos-
phamide group. The adjusted Cox proportional hazard
regression showed a reduced hazard of second progression or
death in the salvage ASCT group compared with weekly
cyclophosphamide (HR: 045, 95% CI 030–066, P < 0001).
Figure 4A shows the Kaplan-Meier curve for PFS2 stratified
by randomisation allocation. Figure 4B extends this by con-
sidering those in the weekly cyclophosphamide group who
had a salvage ASCT post-trial and those who did not (me-
dian PFS2 31 months (95% CI: 24–43) vs. 38 months (32–
48) respectively).
Figure 4C shows a forest plot of the PFS2 results corre-
lated with the cytogenetic analysis at baseline. The treat-
ment effects for those with cytogenetic analysis at baseline
and the ITT population are consistent (HR: 038, 95% CI:
022–066). Whilst an HR is not estimable for the rear-
ranged subgroup, there is significant evidence of hetero-
geneity of treatment effect with MYC rearrangement (LRT:
P = 0016).
The extended median OS follow-up is 70 months (IQR:
55–79 months) with 125 (421%) registered trial patients
having died. Of these, 90 patients have died following ran-
domisation, i.e. 517% of randomized participants have died.
In the salvage ASCT group there have been 40 (449%)
deaths compared to 50 (588%) in the weekly cyclophos-
phamide group. Disease progression was responsible for
633% (salvage ASCT: 600%, weekly cyclophosphamide:
660%) of deaths. Median OS was 67 months [95% CI: 59-
not reached (NR)] for the salvage ASCT group and
55 months (44–67) for the weekly cyclophosphamide group.
Adjusted Cox proportional hazards regression showed a
Table I. (Continued)
Registered
(n = 297)
Salvage ASCT
(n = 89)
Weekly cyclophosphamide
(n = 85)
Randomised
(n = 174)
iFISH cytogenetic results at diagnosis and baseline
Yes 41 (138%) 13 (146%) 17 (200%) 30 (172%)
No 256 (862%) 76 (854%) 68 (800%) 144 (828%)
iFISH cytogenetic results at diagnosis or baseline
Yes 171 (576%) 50 (562%) 54 (635%) 104 (598%)
No 126 (424%) 39 (438%) 31 (365%) 70 (402%)
ASCT, autologous stem-cell transplant; CR, complete response; iFISH, interphase fluorescence in situ hybridization; IQR, inter-quartile range;
ISS, International Staging System; PBSC, peripheral blood stem cells; PR, partial response; sCR, stringent complete response; SD, stable disease;
VGPR, very good partial response.
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Subgroup Analysis Results: Time−To−Progression
Variable
t(4,14) translocation at first relapse
t(11,14) translocation at first relapse
17p deletion at first relapse
13q deletion at first relapse
Hyperdiploidy at first relapse
MYC
iFISH Cytogenetics at first relapse
Overall
Detected
Not Detected
Detected
Not Detected
Detected
Not Detected
Detected
Not Detected
Detected
Not Detected
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Rearranged
Standard
Adverse
Salvage ASCT 
 N (Event)
5 (5)
38 (32)
3 (3)
40 (34)
4 (4)
39 (33)
21 (20)
22 (17)
4 (4)
39 (33)
28 (22)
7 (7)
36 (30)
7 (7)
43 (37)
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44 (40)
17 (16)
28 (25)
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39 (35)
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39 (35)
6 (6)
45 (41)
HR (95% CI)
2.55 (0.23, 28.65)
0.38 (0.22, 0.64)
0.39 (0.03, 4.44)
0.38 (0.23, 0.64)
NE
0.39 (0.23, 0.65)
0.58 (0.28, 1.19)
0.28 (0.13, 0.58)
0.03 (0.00, 0.74)
0.38 (0.22, 0.65)
0.27 (0.14, 0.54)
3.40 (0.56, 20.50)
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Fig 3. TTP and PFS analysis results. (A) TTP by randomised treatment. (B) Forest plot of the subgroup analysis for TTP. (C) PFS by randomised
treatment. (D) Forest plot of the subgroup analysis for PFS. The black squares and horizontal lines represent the hazard ratio (HR) and the asso-
ciated 95% confidence interval (95% CI) of the risk of progression (TTP) and progression or death (PFS) in the Salvage ASCT treatment arm
compared to the weekly cyclophosphamide arm, p(het) represents the P-value from the likelihood ratio test assessing heterogeneity of treatment
effect between subgroups. ASCT, autologous stem-cell transplant; CI, confidence interval; HR, hazard ratio; iFISH, interphase fluorescence in situ
hybridization; NE, not evaluable; PFS, progression-free survival; TTP, time to progression.
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Subgroup Analysis Results: Progression−Free Survival
Variable
t(4,14) translocation at first relapse
t(11,14) translocation at first relapse
17p deletion at first relapse
13q deletion at first relapse
Hyperdiploidy at first relapse
MYC rearrangement at first relapse
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Not Detected
Detected
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Salvage ASCT 
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40 (35)
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44 (40)
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2.55 (0.23, 28.65)
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0.39 (0.24, 0.65)
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Fig 4. PFS2 analysis results. (A) By randomised treatment. (B) By randomised treatment with the weekly cyclophosphamide group separated by
those who receive a subsequent ASCT (sASCT). (C) Forest plot of the subgroup analysis conducted for PFS2. The black squares and horizontal
lines represent the hazard ratio (HR) and the associated 95% confidence interval (95% CI) of the risk of second progression or death in the Sal-
vage ASCT treatment arm compared to the weekly cyclophosphamide arm, p(het) represents the P-value from the likelihood ratio test assessing
heterogeneity of treatment effect between subgroups. ASCT, autologous stem-cell transplant; CI, confidence interval; HR, hazard ratio; iFISH,
interphase fluorescence in situ hybridization; PFS2; second progression-free survival; sASCT, subsequent autologous stem-cell transplant.
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reduced hazard of death in the salvage ASCT group com-
pared with weekly cyclophosphamide (HR: 064, 95% CI:
042–099, P = 00435); a similar result to our previous
shorter-term results (Cook et al, 2016). Figure 5A shows the
Kaplan-Meier curve for OS stratified by randomisation allo-
cation. Figure 5B extends this by considering those in the
weekly cyclophosphamide group who had a subsequent sal-
vage ASCT following the trial and those who did not [me-
dian OS NR months (95% CI: 39-NR) vs. 31 months (22–
39), respectively].
Figure 5C shows a forest plot of the OS results correlated
with cytogenetic analysis at baseline. The treatment effects
for those with cytogenetic analysis at baseline and the ITT
population are consistent (HR: 046, 95% CI: 025–085).
There is significant evidence of heterogeneity of treatment
effect with MYC rearrangement (LRT: P = 0021), in which
the presence of the marker has a deleterious impact on the
randomized treatment effect observed, compared with the
subset of patients without the marker. This deleterious
impact can be seen further in a Kaplan-Meier curve for OS
stratified by whether MYC was rearranged or normal for each
treatment allocation (Figure S3). Whilst del(17p) is shown to
have significant evidence to heterogeneity (LRT: P < 0001)
an exact HR cannot be calculated for the detected subgroup
as only one participant had the marker in the weekly
cyclophosphamide group.
This long-term follow-up analysis has permitted use of a
technique developed for the analysis of drug registration trials,
in which the investigational drug is permitted post-trial in the
control comparator group. In this situation this relates to the
subsequent delivery in later line therapy of salvage transplant
in patients allocated to the weekly cyclophosphamide group.
In the weekly cyclophosphamide group 16 patients (242%)
received a subsequent salvage ASCT as part of their third-line
of therapy, four patients (85%) as part of their fourth-line of
therapy and one patient (63%) as part of a later-line of ther-
apy. These subsequent salvage ASCTs have diluted the allo-
cated treatment effect in terms of OS, rescuing some patients
after their non-transplant consolidation on trial at first relapse.
This can be seen in Fig 5D where there is a difference between
the ITT weekly cyclophosphamide estimate of OS and the
counterfactual estimate of OS for that group accounting for
the subsequent salvage ASCT. The counterfactual estimate of
median OS for the weekly cyclophosphamide group was
52 months (95% CI: 41-NR). This reflects the impact of a sub-
sequent salvage ASCT in 21 of 85 patients (247%) in the
weekly cyclophosphamide group, leading to an improvement
in median OS of 3 months in the ITT estimate of OS. The
Subgroup Analysis Results: PFS2
Variable
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36 (18)
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counterfactual HR for the adjusted analysis is smaller than that
for the ITT analysis (ITT HR: 063, 95% CI: 042–096,
P = 0033; adjusted HR: 052, 95% CI: 029–095), similarly
indicating the rescue effect of a subsequent salvage ASCT.
There was no evidence of the assumption of constant treat-
ment effect being violated in the counterfactual analysis (Fig-
ure S4), as the 95% CI for the estimated survivor functions by
group, where the effect of salvage ASCT was removed, over-
lapped. This could suggest that the effect of a subsequent sal-
vage ASCT is, in fact, similar to that delivered at first relapse,
conditional on a patient surviving to that subsequent line of
treatment. Another possible reason for the limited impact of
later second transplant on these patients is the number of non-
transplanted patients (~79%) who received second generation
immunomodulatory drugs (IMiDs) post-trial. Details of the
therapies given post-trial are shown in Table II. Excluded from
Table II are the small number of patients who received steroids
with or without alkylating agents, local radiotherapy and other
agents used on only one patient per cohort.
Discussion
Depth of response to therapy in MM, especially to below the
level of minimal residual disease detection, is associated with
durability of response and survival in first-line therapy (Lonial
& Anderson, 2014; Munshi et al, 2017). However, several fea-
tures can influence this durability, none more significantly
than the genomic landscape at presentation of disease activity
requiring therapy. Much of this evidence has been generated in
the frontline setting with an accumulation of data demonstrat-
ing the significance in relapsed disease management (Hebraud
et al, 2013). In Myeloma X, the first randomised study of sal-
vage ASCT at first relapse, we have already shown that depth
of response (in relation to TTP and PFS) to a salvage ASCT
equates to a survival advantage (Cook et al, 2016), and in this
report we suggest that genomic adverse markers at relapse also
influence the outcome of second-line therapy. This report
highlights a number of key issues.
The current study provides the first evidence of changes in
the clonal genetic landscape in the setting of ASCT and sal-
vage ASCT. Several publications have highlighted the sub-
clonal nature of MM, and how alternative clones become
dominant at relapse, a feature which may ultimately provide
a rational for changing treatment strategies (Sonneveld et al,
2016). Nonetheless, this evidence is somewhat limited and
anecdotal. We have provided linked serial evidence that
highlights clonal heterogeneity and evolution, in the setting
of a clinical interventional study with access to pre-trial bio-
logical information. Our evidence shows that whilst many
patients, following first relapse after a prior ASCT, retain
their cytogenetic findings from diagnosis, some patients
develop adverse cytogenetic characteristics while others lose
theirs (or they are at least reduced to undetectable levels) – a
feature that to date has not been reported in MM. This high-
lights sub-clonal selection through the use of novel agents
and prior ASCT. The longitudinal study data presented here
helps to confirm the findings of the Intergroupe Franco-
phone du Myelome (Hebraud et al, 2013), but note these
were not observed by the longitudinal German-speaking
Myeloma Multicentre Group (GMMG) study, where acquisi-
tion of additional (adverse) cytogenetic findings (seen in
approximately one in eight of our patients) was well recog-
nised, but where loss of poor prognostic findings (seen in
one in 20 of our patients) was not frequently described
(Merz et al, 2017). Unfortunately, data on MYC rearrange-
ments were not available for patients at diagnosis and evi-
dence for inclusion of 1q21 gain was lacking when Myeloma
X was designed, both of which would further the relevance
of our findings. It has to be borne in mind that the trial
population represents a selective group, given that the entry
criteria stipulated a minimum of 18 months from ASCT to
trial entry (or 12 months if after the trial amendment), thus
potentially excluding those with high-risk genetic disease.
Therefore, it is somewhat surprising that 161% of all regis-
tered patients with baseline cytogenetic data (24 of 149) har-
boured high-risk genetic aberrations, equating to 148% (13
of 88) of those randomised. However, it must be noted that
only half of all registered participants (502%) had cytoge-
netic analysis recorded at baseline, equating to a similar pro-
portion within those randomised.
The primary aim of any genetic analysis in a MM trial is
to highlight prognostic groups (Palumbo et al, 2015), such
that one can define if the experimental arm of a study can
fully restore any durability of response and survival benefit
associated with that intervention (“level the playing field”).
In this analysis, whilst the majority of high-risk markers [del
(17p), t(4;14) and t(14;16)], when considered individually,
do not prevent the PFS and OS advantage of a salvage ASCT
compared to weekly cyclophosphamide, the negative influ-
ence of the poor prognostic marker, MYC rearrangement,
prevails. The level of MYC rearrangements in the study pop-
ulations of key relapse phase 3 studies is not usually
Fig 5. Overall survival analysis results. (A) By randomised treatment. (B) By randomised treatment with the weekly cyclophosphamide group sep-
arated by those who receive a subsequent ASCT (sASCT). (C) Forest plot of the subgroup analysis conducted for OS. The black squares and hori-
zontal lines represent the hazard ratio (HR) and the associated 95% confidence interval (95% CI) of the risk of death in the Salvage ASCT
treatment arm compared to the weekly cyclophosphamide arm, p(het) represents the P-value from the likelihood ratio test assessing heterogeneity
of treatment effect between subgroups. (D) By randomised treatment using the rank-preserving structural failure time model (RPSFTM) to
account for treatment switching from weekly cyclophosphamide to salvage ASCT. ASCT, autologous stem-cell transplant; CI, confidence interval;
HR, hazard ratio; iFISH, interphase fluorescence in situ hybridization; ITT, intention to treat; OS, overall survival; sASCT, subsequent autologous
stem-cell transplant.
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documented (Lonial et al, 2015; Stewart et al, 2015; Dimo-
poulos et al, 2016; Moreau et al, 2016), so defining its uni-
versality of impact becomes difficult. MYC activation, either
through translocation or gain of the MYC locus, results in
deregulation of upstream pathways such as IRF4 or MAPK
(Jovanovic et al, 2018). A better understanding of the mecha-
nisms responsible for MYC deregulation in MM offers the
potential for more targeted approaches, given that high dose
Subgroup Analysis Results: Overall Survival
Variable
t(4,14) translocation at first relapse
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17p deletion at first relapse
13q deletion at first relapse
Hyperdiploidy at first relapse
MYC  rearrangement at first relapse
iFISH Cytogenetics at first relapse
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Not Detected
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Not Detected
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Not Detected
Detected
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Detected
Not Detected
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Rearranged
Standard
Adverse
Salvage ASCT 
 N (Event)
5 (3)
38 (15)
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40 (16)
4 (1)
39 (17)
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alkylating agent therapy used in salvage ASCT has shown
limited effect on the adverse prognostic impact of MYC rear-
rangements. Several such therapeutic strategies for patients
with MM are currently being evaluated in clinical trials,
including Bromodomain and Extra-Terminal (BET) inhibi-
tors (Jovanovic et al, 2018).
In analysing our data, the application of the RPSFTM
methodology, as a post-hoc exploratory analysis, to the
detailed follow-up of patients entered in this trial has pro-
duced evidence that ASCT, even if delayed to second or pos-
sibly third relapse, may be of benefit for patients having
response to first ASCT of greater than 12 months. This is
highly relevant to clinical decision-making in this setting. As
the trial met its primary endpoint early, only 174 eligible
patients were randomised compared to the original estimate
of 320; this resulted in an approximately 45% reduction in
the sample size for the associated scientific studies. Whilst
the baseline characteristics of those with and without cytoge-
netic analysis are similar (Table SI), the subgroup analysis
results should still be interpreted with caution as hypothesis-
generating. However, the findings may be important for the
design of future studies which may compare second ASCT to
current therapies. This is particularly relevant in this study
where the median OS of the control group has lengthened
(but remains significantly shorter than the experimental arm)
with prolonged follow-up and is thought to be as a conse-
quence of more recent novel therapeutic agent development
and incorporation into the standard of care (SoC), such as
second generation IMiDs and proteasome inhibitors. This
too could explain the observed difference between PFS2 and
OS, with the maturity of follow-up presented in this last
analysis. Measuring OS in clinical interventional studies,
whilst of great importance, has become more difficult given
the plethora of novel agents accessible in both SoC and
through clinical interventional studies. In essence, not only
are there treatment switch effects, from participants in the
control arm accessing the study’s “experimental treatment”
following the completion of their trial treatment, i.e. salvage
ASCT in the third-line or later, but also clear evidence of
post-trial selection bias, in that patients with better perfor-
mance status and stable haematopoietic reserve are able to
access clinical trials and thus be exposed to newer efficacious
agents in the phase 2 or even phase 3 setting, where as those
who are not as fit or as biologically robust, may not. As
such, the post-trial therapeutic landscape provides significant
heterogeneity and can diminish the survival impact from the
primary trial intervention. However, each of these findings
are beyond the main randomised question of the study and
should be validated.
In summary, we have shown that the gains in TTP, PFS
and OS observed from Myeloma X are robust, and con-
firmed at later follow-up. This remains the only randomised
evidence for salvage ASCT ahead of the reporting of GMMG
ReLApsE trial (ISRCTN16345835). The ReLApsE study has
an immunomodulatory agent control group, which is widely
considered to be superior to weekly cyclophosphamide, and
should provide further evidence for or against salvage ASCT
with contemporary therapies. The genomic landscape with
relapsing disease can vary from that seen at diagnosis with
both loss and gain of adverse iFISH prognostic factors and
confirm that the gain of such factors does affect prognosis in
patients at first relapse. In particular, we highlight the
adverse impact of MYC re-arrangements, and that the cur-
rent clinical interventions do not circumvent this adversity,
highlighting the need for newer targeted strategies for this
sub-group of patients. Additionally, we present evidence sug-
gesting that a second, salvage transplant can be of benefit for
OS, even if delivered later than first relapse.
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Figure S2. Kaplan-Meier curve for TTP by whether
MYC was normal or rearranged at first relapse in patients
randomised to (a) salvage ASCT and (b) weekly cyclophos-
phamide.
Figure S3. Kaplan-Meier curve for OS by whether MYC
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